Chemical modification of Class II G protein-coupled receptor ligands: Frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies

Pharmacology and Therapeutics

Volumn 125, Issue 1, 2010, Pages 39-54

  Chapter, Megan C ^a   White, Caitlin M ^a   DeRidder, Angela ^a,b   Chadwick, Wayne ^a   Martin, Bronwen ^b   Maudsley, Stuart ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Bioavailability; G protein coupled receptor; Instability; Modification; Pharmacotherapeutic; Secretin like

Indexed keywords

BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CALCITONIN; CALCITONIN DERIVATIVE; CALCITONIN GENE RELATED PEPTIDE DERIVATIVE; CJC 1295; CORTICOTROPIN RELEASING FACTOR; EXENDIN 4; FATTY ACID; G PROTEIN COUPLED RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; JI 38; LIRAGLUTIDE; METFORMIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PEPTIDE DERIVATIVE; SECRETIN; SECRETIN DERIVATIVE; SULFONYLUREA; T 0632; TP 3805; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE;

ACYLATION; AMINO ACID SUBSTITUTION; AMYOTROPHIC LATERAL SCLEROSIS; AUTISM; AUTOIMMUNE DISEASE; CHEMICAL MODIFICATION; CHRONIC INFLAMMATION; DIABETES MELLITUS; DRUG HALF LIFE; DRUG INDICATION; DRUG TARGETING; HUMAN; HUNTINGTON CHOREA; LIGAND BINDING; NEUROENDOCRINE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; SCHIZOPHRENIA; SOLID TUMOR;

AMINO ACID SEQUENCE; ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; NEUROSECRETORY SYSTEMS; NEUROTRANSMITTER AGENTS; PEPTIDE HORMONES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GASTROINTESTINAL HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 72049097669     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.07.006     Document Type: Review

References (207)

1. Aaboe K., Krarup T., Madsbad S., and Holst J. GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes Metab 10 (2008) 994-1003
2. Aiyar N., Daines R.A., Disa J., Chambers P.A., Sauermelch C.F., Quiniou M., et al. Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J Pharmacol Exp Ther 296 (2001) 768-775
3. Alba M., Schally A., and Salvatori R. Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog. Endocrinology 146 (2005) 1506-1513
4. Amara S., Jonas V., and Rosenfeld M. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298 (1982) 240-244
5. Arborelius L., Owens M., Plotsky P., and Nemeroff C. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160 (1999) 1-12
6. Aton S., Colwell C., Harmar A., Waschek J., and Herzog E. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat Neurosci 8 (2005) 476-483
7. Banks W., Goulet M., Rusche J., Niehoff M., and Boismenu R. Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse. J Pharmacol Exp Ther 302 (2002) 1062-1069
8. Baum J., Simons Jr. B., Unger R., and Madison L. Localization of glucagon in the alpha cells in the pancreatic islet by immunofluorescent technics. Diabetes 11 (1962) 371-374
9. Beltowski J., and Jamroz A. Adrenomedullin-what do we know 10 years since its discovery?. Pol J Pharmacol 56 (2004) 5-27
10. Bensal P., and Wang Q. Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab 295 (2008) E751-E761
11. Bissette G., Reynolds G., Kilts C., Widerlöv E., and Nemeroff C. Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations. JAMA 254 (1985) 3067-3069
12. Biswas S., Buteau J., and Greene L. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem Res 33 (2008) 1845-1851
13. Bourgault S., Vaudry D., Botia B., Couvineau A., Laburthe M., Vaudry H., et al. Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 29 (2008) 919-932
14. Brain S., and Grant A. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 84 (2004) 903-934
15. Brenneman D., and Eiden L. Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc Natl Acad Sci U S A 83 (1986) 1159-1162
16. Brown T., Colwell C., Waschek J., and Piggins H. Disrupted neuronal activity rhythms in the suprachiasmatic nuclei of vasoactive intestinal polypeptide-deficient mice. J Neurophysiol 97 (2007) 2553-2558
17. Burcelin R., Cani P., and Knauf C. Glucagon-like peptide-1 and energy homeostasis. J Nutr 137 (2007) 2534S-2538S
18. Cao J., Papadopoulou N., Kempuraj D., Boucher W.S., Sugimoto K., Cetrulo C.L., et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 174 (2005) 7665-7675
19. Caraglia M., Carteni M., Dicitore A., Cassesse D., De Maria S., Ferranti P., et al. Experimental study on vasoactive intestinal peptide (VIP) and its diaminopropane bound (VIP-DAP) analog in solution. Amino Acids 35 (2008) 275-281
20. Cavallaro S., Copani A., D'Agata V., Musco S., Petralia S., Ventra C., et al. Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons. Mol Pharmacol 50 (1996) 60-66
21. Champion H., Duperier C., Fitzgerald W., Lambert D., Murphy W., Coy D., et al. [MPR14]-rADM (14-50), a novel analog of adrenomedullin possesses potent vasodilator activity in the hindlimb vascular bed of the cat. Life Sci 59 (1996) 1-7 PL
22. Chan E.-C., Falconer J., Madsen G., Rice K.C., Webster E.L., Chrousos G.P., et al. A corticotrophin-releasing hormone Type I receptor antagonist delays parturition in sheep. Endocrinology 139 (1998) 3357-3360
23. Chen R., Lewis K., Perrin M., and Vale W. Expression and cloning of a human corticotropin-releasing factor receptor. Proc Natl Acad Sci U S A 90 (1993) 8967-8971
24. Chen C., Dagnino R., Desouza E.B., Grigoriadis D.E., Huang C.Q., Kim K.I., et al. Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor(1) receptor antagonists. J Med Chem 39 (1996) 4358-4360
25. Cheng W., and Lim L. Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol. J Pharm Sci 98 (2009) 1438-1451
26. Chunxiao W., Jingjing L., Yire X., Min D., Zhaohui W., Gaofu Q., Xiangchun S., et al. Study on preparation and activity of a novel recombinant human parathyroid hormone(1-34) analog with N-terminal Pro-Pro extension. Regul Pept 141 (2007) 35-43
27. Clark A., Chargé S., Badman M., and de Koning E. Islet amyloid in type 2 (non-insulin-dependent) diabetes. APMIS 104 (1996) 12-18
28. Clemens T., Cormier S., Eichinger A., Endlich K., Fiaschi-Taesch N., Fischer E., et al. Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets. Br J Pharmacol 134 (2001) 1113-1136
29. Dangoor D., Rubinraut S., Fridkin M., and Gozes I. Novel extended and branched N-terminal analogs of VIP. Regul Pept 137 (2006) 42-49
30. Dangoor D., Rubinraut S., Fridkin M., and Gozes I. Novel analogs of VIP with multiple C-terminal domains. Peptides 28 (2007) 1622-1630
31. Dangoor D., Biondi B., Gobbo M., Vachutinski Y., Fridkin M., Gozes I., et al. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. J Pept Sci 14 (2008) 321-328
32. Delgado M., Reduta A., Sharma V., and Ganea D. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. J Leukoc Biol 75 (2004) 1122-1130
33. Delgado M., Varela N., and Gonzalez-Rey E. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia 56 (2008) 1091-1103
34. Denker P.S., and Dimarco P.E. Exenatide (exendin-4)-induced pancreatitis. A case report. Diabetes Care 29 (2006) 471
35. Ding K., Zhong Q., Xie D., Chen H., Della-Fera M., Bollag R., et al. Effects of glucose-dependent insulinotropic peptide on behavior. Peptides 27 (2006) 2750-2755
36. Doga M., Bonadonna S., Gola M., Mazziotti G., and Giustina A. Growth hormone deficiency in the adult. Pituitary 9 (2006) 305-311
37. Drucker D. Glucagon-like peptides. Diabetes 47 (1998) 159-169
38. Dunn A., and Berridge C. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?. Brain Res Brain Res Rev 15 (1990) 71-100
39. Dunphy J., Taylor R., and Fuller P. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 141 (1998) 179-186
40. Edelman S. Optimizing diabetes treatment using an amylin analogue. The Diabetes Educator 34 (2008) 4S
41. Elliott-Hunt C., Kazlauskaite J., Wilde G., Grammatopoulos D., and Hillhouse E. Potential signalling pathways underlying corticotrophin-releasing hormone-mediated neuroprotection from excitotoxicity in rat hippocampus. J Neurochem 80 (2002) 416-425
42. Epand R., Orlowski R., and Epand R. The biological potency of a series of analogues of human calcitonin correlates with their interactions with phospholipids. Biopolymers 76 (2004) 258-265
43. Fahrenkrug J. PACAP-a multifaceted neuropeptide. Chronobiol Int 23 (2006) 53-61
44. Feinglos M., Saad M., Pi-Sunyert F., An B., and Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabetic Medicine 22 (2005) 1016-1023
45. Felley C., Qian J., Mantey S., Pradhan T., and Jensen R. Chief cells possess a receptor with high affinity for PACAP and VIP that stimulates pepsinogen release. Am J Physiol 263 (1992) G901-G907
46. Fremeau Jr. R.T., Jensen R., Charlton C., Miller R., O'Donohue T., and Moody T. Secretin: specific binding to rat brain membranes. J Neurosci 3 (1983) 1620-1625
47. Gallai V., Sarchielli P., Floridi A., Franceschini M., Codini M., Glioti G., et al. Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15 (1995) 384-390
48. Gault V., Kerr B., Irwin N., and Flatt P. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochem Pharmacol 75 (2008) 2325-2333
49. Gautier J., Choukem S., and Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 34 Suppl 2 (2008) S65-S72
50. Gensure R., Shimizu N., Tsang J., and Gardella T. Identification of a contact site for residue 19 of parathyroid hormone (PTH) and PTH-related protein analogs in transmembrane domain two of the type 1 PTH receptor. Mol Endocrinol 17 (2003) 2647-2658
51. Gómez J. Growth hormone and insulin-like growth factor-I as an endocrine axis in Alzheimer's disease. Endocr Metab Immune Disord Drug Targets 8 (2008) 143-151
52. Gonzalez B., Basille M., Vaudry D., Fournier A., and Vaudry H. Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts. Neuroscience 78 (1997) 419-430
53. Gonzalez-Rey E., Varela N., Chorny A., and Delgado M. Therapeutic approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr Pharm Des 13 (2007) 1113-1139
54. Goodyer C., de Stéphano L., Lai W., Guyda H., and Posner B. Characterization of insulin-like growth factor receptors in rat anterior pituitary, hypothalamus, and brain. Endocrinology 114 (1984) 1187-1195
55. Grammatopoulos D., and Chrousos G. Functional characteristics of CRH receptors and potential clinical application of CRH-receptor antagonists. Trends Endocrinol Metab 13 (2002) 436-444
56. Gray S.L., Yamaguchi N., Vencova P., and Sherwood N.M. Temperature sensitive phenotype in mice lacking pituitary adenylate cyclase activating polypeptide. Endocrinology 143 (2002) 3946-3954
57. Green B., and Flatt P. Incretin hormone mimetics and analogues in diabetes. Best Pract Res Clin Endocrinol Metab 21 (2007) 497-516
58. Grinevich V., Fournier A., and Pelletier G. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on corticotrophin-releasing hormone (CRH) gene expression in the rat hypothalamic paraventricular nucleus. Brain Res 773 (1997) 190-196
59. Hansotia T., and Drucker D. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 128 (2005) 125-134
60. Hanstein R., Lu A., Wurst W., Holsboer F., Deussing J.M., Clement A.B., et al. Transgenic overexpression of corticotropin releasing hormone provides partial protection against neurodegeneration in an in vivo model of acute excitotoxic stress. Neuroscience 156 (2008) 712-721
61. Harmar A., Marston H., Shen S., Spratt C., West K., Sheward W., et al. The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 109 (2002) 497-508
62. Harvey S., and Hayer S. Parathyroid hormone binding sites in the brain. Peptides 14 (1993) 1187-1191
63. Hashimoto H. Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system. Yakugaku Zasshi 122 (2002) 1109-1121
64. Hashimoto R., Hashimoto H., Shintani N., Chiba S., Hattori S., Okada T., et al. Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. Mol Psychiatry 12 (2007) 1026-1032
65. Heuser I., Baronti F., Marin C., Ma N., Merriam G., Chase T., et al. Growth hormone secretion in Alzheimer's disease: 24-hour profile of basal levels and response to stimulation and suppression studies. Neurobiol Aging 13 (1992) 255-260
66. Hikichi T., Yamamoto Y., Tsutsumi T., Isogawa K., and Akiyoshi J. Conditioned fear freezing behavior suppression treated by CRH1 receptor antagonist. Jpn J Psychopharm 17 (1997) 284
67. Hill J.M., Hauser J.M., Sheppard L.M., Abebe D., Spivak-Pohis I., Kushnir M., et al. Blockade of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. J Mol Neurosci 33 (2007) 278-283
68. Hirasawa T., Nakamura T., Mizushima A., Morita M., Ezawa I., Miyakawa H., et al. Adverse effects of an active fragment of parathyroid hormone on rat hippocampal organotypic cultures. Br J Pharmacol 129 (2000) 21-28
69. Holsboer F., and Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 17 (1996) 187-205
70. Holz G., and Chepurny O. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 10 (2003) 2471-2483
71. Horvath K., Stefanatos G., Sokoloski K.N., Wachtel R., Nabors L., and Tildon J.T. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys 9 (1998) 9-15
72. Huang C., Sun L., Moonga B., and Zaidi M. Molecular physiology and pharmacology of calcitonin. Cell Mol Biol 52 (2006) 33-43
73. Ionescu M., and Frohlman L.A. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 91 (2006) 4792-4797
74. Irwin D. Molecular evolution of proglucagon. Regul Pept 98 (2001) 1-12
75. Irwin N., Green B., Mooney M., Greer B., Harriott P., Bailey C., et al. A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. J Pharmacol Exp Ther 314 (2005) 1187-1194
76. Isogawa K., Akiyoshi J., Hikichi T., Yamamoto Y., Tsutsumi T., and Nagayama H. Effect of corticotrophin releasing factor receptor 1 antagonist on extracellular norepinephrine, dopamine and serotonin in hippocampus and prefrontal cortex of rats in vivo. Neuropeptides 34 (2000) 234-239
77. Izdebski J., Pinski J., Horvath J., Halmos G., Groot K., and Schally A. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A 92 (1995) 4872-4876
78. Jhamanadas J., and MacTavish D. Antagonist of the amylin receptor blocks beta-amyloid toxicity in rat cholinergic basal forebrain neurons. J Neurosci 24 (2004) 5579-5584
79. Kastin A., Akerstrom V., and Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood brain barrier. J Mol Neurosci 18 (2002) 7-14
80. Kato J., Tsuruda T., Kitamura K., and Eto T. Adrenomedullin: a possible autocrine or paracrine hormone in the cardiac ventricles. Hypertens Res 26 Suppl 1 (2003) S113-S119
81. Kawase T., Okuda K., and Burns D. Immature osteoblastic MG63 cells possess two calcitonin gene-related peptide receptor subtypes that respond differently to [Cys(Acm)2, 7] calcitonin gene-related peptide and CGRP8-37. Am J Physiol Cell Physiol 289 (2005) 811-818
82. Kern J., Espinoza E., and Trivedi M. The effectiveness of secretin in the management of autism. Expert Opin Pharmacother 5 (2004) 379-387
83. Kiaris H., Schally A., and Varga J. Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. Neoplasia 2 (2000) 242-250
84. Kineman R. Antitumorigenic actions of growth hormone-releasing hormone antagonists. Proc Natl Acad Sci U S A 97 (2000) 532-534
85. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192 (1993) 553-560
86. Knopp J., Diner B., Blitz M., Lyritis G., and Rowe B. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 16 (2005) 1281-1290
87. Knudsen L., Nielsen P., Huusfeldt P., Johansen N., Madsen K., Pedersen F., et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43 (2000) 1664-1669
88. Knudsen L.B., Kiel D., Teng M., Behrens C., Bhumralkar D., Kodra J.T., et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A 104 (2007) 937-942
89. Köves K., Arimura A., Somogyvári-Vigh A., Vigh S., and Miller J. Immunohistochemical demonstration of a novel hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide, in the ovine hypothalamus. Endocrinology 127 (1990) 264-271
90. Kruger D., Gatcomb P., and Owen S. Clinical implications of amylin and amylin deficiency. Diabetes Educ 25 (1999) 389-397
91. LaBuda C., and Usdin T. Tuberoinfundibular peptide of 39 residues decreases pain-related affective behavior. Neuroreport 15 (2004) 1779-1782
92. Lanfranco F., Gianotti L., Giordano R., Pellegrino M., Maccario M., and Arvat E. Ageing, growth hormone and physical performance. J Encrinol Invest 26 (2003) 861-872
93. Lanfranco F., Gianotti L., Giordano R., Pellegrino M., Maccario M., and Arvat E. Ageing, growth hormone and physical performance. J Encrinol Invest 26 (2003) 861-872
94. Ladram A., Besne I., Breton L., Lcharriere O., Nicolas P., and Amiche M. Pharmacologic study of C-terminal fragments of frog skin calcitonin gene-related peptide. Peptides 29 (2008) 1150-1156
95. Lange M., Müller J., Svendsen O., Kastrup K., Juul A., and Feldt-Rasmussen U. The impact of idiopathic childhood-onset growth hormone deficiency (GHD) on bone mass in subjects without adult GHD. Clin Endocrinol (Oxf) 62 (2005) 18-23
96. Langer I., Gregoire F., Nachtergaol I., De Neef P., Vertongen P., and Robberecht P. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency. Peptides 25 (2004) 275-278
97. Langlet C., Gaspard N., Nachtergael I., Robberecht P., and Langer I. Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells. Peptides 25 (2004) 2079-2086
98. Lassen L., Jacobsen V., Haderslev P., Sperling B., Iversen H., Olesen J., et al. Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain 9 (2008) 151-157
99. Lee S.-H., Lee S., Youn Y., Na D., Chae S., Byun Y., et al. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjugate Chem 16 (2005) 377-382
100. Lelievre V., Seksenyan A., Nobuta H., Yong W.H., Chhith S., et al. Disruption of the PACAP gene promotes medulloblastoma in ptc1 mutant mice. Dev Biol 313 (2008) 359-370
101. Lesch K., Ihl R., Frölich L., Rupprecht R., Müller U., Schulte H., et al. Endocrine responses to growth hormone releasing hormone and corticotrophin releasing hormone in early-onset Alzheimer's disease. Psychiatry Res 33 (1990) 107-112
102. Lezoualc'h F., Engert S., Berning B., and Behl C. Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB. Mol Endocrinol 14 (2000) 147-159
103. Li, S., Grinevich, V., Fournier, A., & Pelletier, G. (1996). Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on gonadotropin-releasing hormone and somatostatin gene expression in the rat brain. Mol Brain Res 41, 157-162.
104. Liaw C., Lovenberg T., Barry G., Oltersdorf T., Grigoriadis D., and de Souza E. Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology 137 (1996) 72-77
105. Likar R., Mousa S.A., Steinkellner H., Koppert W., Phillippitsch G., Stein C., et al. Involvement of intra-ocular corticotropin-releasing hormone in postoperative pain modulation. Clin J Pain 23 (2007) 136-142
106. Loh D., Abad C., Colwell C., and Waschek J. Vasoactive intestinal polypeptide is critical for circadian regulation of glucocorticoids. Neuroendocrinology 88 (2008) 246-255
107. Love J.W. Peptic ulceration may be a hormonal deficiency disease. Med Hypotheses 70 (2008) 1103-1107
108. Lund P., Goodman R., Dee P., and Habener J. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci USA 79 (1982) 345-349
109. Lutz-Bucher B., Monnier D., and Koch B. Evidence for the presence of receptors for pituitary adenylate cyclase-activating polypeptide in the neurohypophysis that are positively coupled to cyclic AMP formation and neurohypophyseal hormone secretion. Neuroendocrinology 64 (1996) 153-161
110. Macica C.M., and Broadus A.E. PTHrP regulates cerebral blood flow and is neuroprotective. Am J Physiol Regul Integr Comp Physiol 284 (2003) 1019-1020
111. 3 in exocytosis. J Biol Chem 263 (1988) 2123-2126
112. Mangin M., Ikeda K., and Broadus A. Structure of the mouse gene encoding parathyroid hormone-related protein. Gene 95 (1990) 195-202
113. Martin B., Lopez de Maturana R., Brenneman R., Walent T., Mattson M.P., and Maudsley S. Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolec Med 7 (2005) 3-36
114. Martin B., Golden E., Keselman A., Stone M., Mattson M.P., Egan J.M., et al. Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. Histol Histopathol 23 (2008) 237-250
115. Martin B., Golden E., Carlson O.D., Pistell P., Zhou J., Kim W., et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies and extends survival in a mouse model of Huntington's disease. Diabetes 58 (2009) 318-328
116. Masuo Y., Ohtaki T., Masuda Y., Tsuda M., and Fujino M. Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections. Brain Res 575 (1992) 113-123
117. Mattson M., Maudsley S., and Martin B. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res Rev 3 (2004) 445-464
118. Maudsley S., Martin B., and Luttrell L.M. The origins of diversity and specificity in G protein-coupled receptor signaling. J Pharmacol Exp Ther 314 (2005) 485-494
119. Mayo K., Vale W., Rivier J., Rosenfeld M., and Evans R. Expression-cloning and sequence of a cDNA encoding human growth hormone-releasing factor. Nature 306 (1983) 86-88
120. Merchenthaler I. Corticotropin releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution. Peptides 5 (1984) 53-69
121. Merchenthaler I., Vigh S., Schally A., and Petrusz P. Immunocytochemical localization of growth hormone-releasing factor in the rat hypothalamus. Endocrinology 114 (1984) 1082-1085
122. McLean M., and Smith R. Corticotropin-releasing hormone and human parturition. Reproduction 121 (2001) 493-501
123. McQueen J., and Heck A. Secretin for the treatment of autism. Ann Pharmacother 36 (2002) 305-311
124. Millar R.P., Lu Z.L., Pawson A.J., Flanaga C.A., Morgan K., and Maudsley S. Gonadotropin-releasing hormone receptors. Endocr Rev 25 (2004) 235-275
125. Miyata A., Arimura A., Dahl R., Minamino N., Uehara A., Jiang L., et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulate adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164 (1989) 567-574
126. Murase T., Kondo K., Otake K., and Oiso Y. Pituitary adenylate cyclase-activating polypeptide stimulates arginine vasopressin release in conscious rats. Neuroendocrinology 57 (1993) 1092-1096
127. Mutt V. Chemistry, isolation and purification of gastrointestinal hormones. Biochem Soc Trans 8 (1980) 11-14
128. Nemeroff C., Krishnan K., Belkin B., Ritchie J., Clark C., Vale W., et al. Growth hormone response to growth hormone releasing factor in Alzheimer's disease. Neuroendocrinology 50 (1989) 663-666
129. Nishijima I., Yamagata T., Spencer C., Weeber E., Alekseyenko O., Sweatt J., et al. Secretin receptor-deficient mice exhibit impaired synaptic plasticity and social behavior. Hum Mol Genet 15 (2006) 3241-3250
130. Nishikimi T., and Matsuoka H. Cardiac adrenomedullin: its role in cardiac hypertrophy and heart failure. Curr Med Chem Cardiovasc Hematol Agents 3 (2005) 231-242
131. Nyberg J., Anderson M., Meister B., Alborn A., Ström A., Brederlau A., et al. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci 25 (2005) 1816-1825
132. Nyberg J., Jacobsson C., Anderson M., and Eriksson P. Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J Neurosci Res 85 (2007) 2099-2119
133. Odegard P.S., Setter S.M., and Iltz J.L. Update in the pharmacologic treatment of Diabetes Mellitus: focus on pramlintide and exentide. Diabetes Educator 32 (2006) 693-705
134. Offen D., Sherki Y., Melamed E., Fridkin M., Brenneman D., and Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res 854 (2000) 257-262
135. O'Hartem F., Hunter K., Gault V., Irwin N., Green B., Greer B., et al. Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice. Am J Physiol Endocrinol Metab 292 (2007) 1674-1682
136. Okazaki R. Parathyroid disorders and bone metabolism. Clin Calcim 15 (2005) 66-72
137. Okazaki M., Ferrandon S., Vilardaga J., Bouxsein M., Potts J., and Gardella T. Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. PNAS 105 (2008) 16525-16530
138. Onoue S., Yamada S., and Yajima T. Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD. Peptides 28 (2007) 1640-1650
139. Onoue S., Misaka S., and Yamada S. Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn Schmiedebergs Arch Pharmacol 377 (2008) 579-590
140. Otto-Buczkowska E., Mazur-Dworzecka U., and Dworzecki T. Role of amylin in glucose homeostasis and its perspective use in diabetes management. Przegl Lek 65 (2008) 135-139
141. Owens M., and Nemeroff C. Physiology and pharmacology of corticotrophin-releasing factor. Pharmacol Rev 43 (1991) 425-473
142. Parkinson D., and Thakker R. A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism. Nat Genet 1 (1992) 149-152
143. Patel N.C., Yeh J.Y., Shepherd M.D., and Crismon M.L. Secretin treatment for autistic disorder: a critical analysis. Pharmacotherapy 22 (2002) 905-914
144. Pedersen W., McCullers D., Culmsee C., Haughey N., Herman J., and Mattson M. Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease. Neurobiol Dis 8 (2001) 492-503
145. Poole K., and Reeve J. Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 5 (2005) 612-617
146. Pomara N., Singh R., Deptula D., LeWitt P., Bissette G., Stanley M., et al. CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: its relationship to severity of dementia and monoamine metabolites. Biol Psychiatry 26 (1989) 500-504
147. Pratley R., and Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 5 (2008) 73-94
148. Qin H., and Yang F. Calcitonin may be a useful therapeutic agent for osteoclastogenesis syndromes involving premature eruption of the tooth. Med Hypotheses 70 (2008) 1048-1050
149. Reed H., Meyer-Spasche A., Cutler D., Coen C., and Piggins H. Vasoactive intestinal polypeptide (VIP) phase-shifts the rat suprachiasmatic nucleus clock in vitro. Eur J Neurosci 13 (2001) 839-843
150. Reglodi D., Tamas A., Somogyvari-Vigh A., Szanto Z., Kertes E., Lenard L., et al. Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia. Peptides 23 (2002) 2227-2234
151. Reglödi D., Lubics A., Kiss P., Lengvári I., Gaszner B., Tóth G., et al. Effect of PACAP in 6-OHDA-induced injury of the substantia nigra in intact young and ovariectomized female rats. Neuropeptides 40 (2006) 265-274
152. Reichlin S. Neuroendocrine significance of vasoactive intestinal polypeptide. Ann N Y Acad Sci 527 (1988) 431-449
153. Rekasi Z., Varga J., Schally A., Halmos G., Armatis P., Groot K., et al. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. Endocrinology 141 (2000) 2120-2128
154. Riepl R., and Lehnert P. The mediators of bile action on the exocrine pancreas. Scand J Gastroenterol 28 (1993) 369-374
155. Roe S., McGowan E., and Rothwell N. Evidence for the involvement of corticotrophin-releasing hormone in the pathogenesis of traumatic brain injury. Eur J Neurosci 10 (1998) 553-559
156. Rosenfeld R., Ceda G., Wilson D., Dollar L., and Hoffman A. Characterization of high affinity receptors for insulin-like growth factors I and II on rat anterior pituitary cells. Endocrinology 114 (1984) 1571-1575
157. Sawchenko P., Swanson L., Rivier J., and Vale W. The distribution of growth-hormone-releasing factor (GRF) immunoreactivity in the central nervous system of the rat: an immunohistochemical study using antisera directed against rat hypothalamic GRF. J Comp Neurol 237 (1985) 100-115
158. Schmitz O., Brock B., and Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 (2004) S233-S238
159. Schiöth H.B., and Fredriksson R. The GRAFS classification system of G protein coupled receptors in comparative perspective. Gen Comp Endocrinol 142 (2005) 94-101
160. Seki Y., Suzuki Y., Baskaya M., Kano T., Saito K., Takayasu M., et al. The effects of pituitary adenylate cyclase-activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs. Eur J Pharmacol 275 (1995) 259-266
161. Selim A., Mahon M., Juppner H., Bringhurst F., and Divieti P. Role of calcium channels in carboxyl-terminal parathyroid hormone receptor signaling. Am J Physiol Cell Physiol 291 (2006) C114-C121
162. Severs J., and Froland W. Dimerization of PACAP peptide analogue in DMSO via asparagine and aspartic acid residues. J Pharm Sci 97 (2008) 1246-1256
163. Sherwood N., Krueckl S., and McRory J. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21 (2000) 619-670
164. Shibasaki T., Hotta M., Masuda A., Imaki T., Obara N., Hizuka N., et al. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly. J Clin Endocrinol Metab 63 (1986) 167-173
165. Shimizu N., Dean T., Khatri A., and Gardella T. Amino-terminal parathyroid hormone fragment analogs containing alpha, alpha-di-alkyl amino acids at positions 1 and 3. J Bone Miner Res 19 (2004) 2078-2086
166. Shin Y.K., Martin B., Golden E., Dotson C.D., Maudsley S., Kim W., et al. Modulation of taste sensitivity by GLP-1 signaling. J Neurochem 106 (2008) 455-463
167. Shintani N., Mori W., Hashimoto H., Imai M., Tanaka K., Tomimoto S., et al. Defects in reproductive functions in PACAP-deficient female mice. Regul Pept 109 (2002) 45-48
168. Siegel E.G., Scharf G., Gallwitz B., Mentlein R., Morys-Wortmann C., Folsch U.R., et al. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets. Eur J Clin Invest 29 (1999) 610-614
169. Siminoski K., and Josse R. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis. CMAJ 155 (1996) 962-965
170. Somogyvári-Vigh A., and Reglodi D. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr Pharm Des 10 (2004) 2861-2889
171. Sorg O., and Magistretti P. Vasoactive intestinal peptide and noradrenaline exert long-term control on glycogen levels in astrocytes: blockade by protein synthesis inhibition. J Neurosci 12 (1992) 4923-4931
172. Spyroulias G., Papazacharias S., Pairas G., and Cordopatis P. Monitoring the structural consequences of Phe12 → d-Phe and Leu15 → Aib substitution in human/rat corticotropin releasing hormone. Implications for design of CRH antagonists. Eur J Biochem 269 (2002) 6009-6019
173. Staines D.R. Do vasoactive neuropeptide autoimmune disorders explain pyridostigmine's association with Gulf War syndrome?. Med Hypotheses 65 (2005) 591-594
174. Staines D.R. Is Parkinson's disease an autoimmune disorder of endogenous vasoactive neuropeptides?. Med Hypotheses 69 (2007) 1208-1211
175. Staines D.R. Are multiple sclerosis and amyotrophic lateral sclerosis autoimmune disorders of endogenous vasoactive neuropeptides?. Med Hypotheses 70 (2008) 413-418
176. Stinus L., Cador M., Zorrilla E.P., and Koob G.F. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 30 (2005) 90-98
177. Ströhle A., and Holsboer F. Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 36 (2003) S207-S214
178. Svoboda M., Tastenoy M., Vertongen P., and Robberecht P. Relative quantitative analysis of glucagon receptor mRNA in rat tissues. Mol Cell Endocrinol 105 (1994) 131-137
179. Swanson L., and Simmons D. Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: a hybridization histochemical study in the rat. J Comp Neurol 285 (1989) 413-435
180. Teichman S., Neale A., Lawrence B., Gagnon C., Castaigne J.-P., and Frohman L. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrin and Metab 91 (2006) 799-805
181. Thorner M., Chapman I., Gaylinn B., Pezzoli S., and Hartman M. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. Recent Prog Horm Res 52 (1997) 215-244 discussion 244-246
182. Tibaduiza E.C., Chen C., and Beinborn M. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J Biol Chem 276 (2001) 37787-37793
183. Usdin T., Hoare S., Wang T., Mezey E., and Kowalak J. TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus. Nat Neurosci 2 (1999) 941-943
184. Vale W., Spiess J., Rivier C., and Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotrophin and beta-endorphin. Science 213 (1981) 1394-1397
185. Varga J., Schally A., Csernus V., Zarándi M., Halmos G., and Rékási Z. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci U S A 96 (1999) 692-697
186. Vaudry D., Gonzalez B., Basille M., Pamantung T., Fontaine M., Fournier A., et al. The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32. Proc Natl Acad Sci U S A 97 (2000) 13390-13395
187. Vgontzas A.N., Bixler E.O., Wittman A.M., Zachman K., Lin H.-M., Vela-Bueno A., et al. Middle-aged men show higher sensitivity of sleep to the arousing effects of corticotropin-releasing hormone than young men: clinical implications. J Clin Endocrinol Metab 86 (2001) 1489-1495
188. Villalba M., Bockaert J., and Journot L. Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J Neurosci 17 (1997) 83-90
189. Vilsbøll T., Krarup T., Madsbad S., and Holst J. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114 (2003) 115-121
190. Vilsbøll T., Knop F., Krarup T., Johansen A., Madsbad S., Larsen S., et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 88 (2003) 4897-4903
191. Volpi R., Caffarra P., Scaglioni A., Boni S., Saginario A., Chiodera P., et al. Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease. Neuropsychobiology 35 (1997) 79-83
192. Vrbikova J., Hill M., Bendlova B., Grimmichova T., Dvorakova K., Vondra K., et al. Incretin levels in polycystic ovary syndrome. Endocrinology 159 (2008) 121-127
193. Wagner C., Caplan S.R., and Tannenbaum G.S. Interactions of ghrelin signaling pathways with the growth hormone neuroendocrine axis: a new and experimentally tested model. J Mol Endocrinol (2009) 10.1677/JME-09-0023
194. Wajcberg E., and Tavaria A. Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 10 (2009) 135-142
195. Wapnir R., and Teichberg S. Regulation mechanisms of intestinal secretion: implications in nutrient absorption. J Nutr Biochem 13 (2002) 190-199
196. Weaver D., Deeds J., Lee K., and Segre G. Localization of parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor mRNAs in rat brain. Brain Res Mol Brain Res 28 (1995) 296-310
197. Weir E., Brines M., Ikeda K., Burtis W., Broadus A., and Robbins R. Parathyroid hormone-related peptide gene is expressed in the mammalian central nervous system. Proc Natl Acad Sci U S A 87 (1990) 108-112
198. Wimalawansa S. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev Neurobiol 11 (1997) 167-239
199. Xiao Q., Giguere J., Parisien M., Jeng W., St-Pierre S.A., Brubaker P.L., et al. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40 (2001) 2860-2869
200. Xie D., Cheng H., Hamrick M., Zhong Q., Ding K., Correa D., et al. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 37 (2005) 759-769
201. Xie D., Zhong Q., Ding K., Cheng H., Williams S., Correa D., et al. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone 40 (2007) 1352-1360
202. Yamagata T., Urano H., Weeber E., Nelson D., and Nishijima I. Impaired hippocampal synaptic function in secretin deficient mice. Neuroscience 154 (2008) 1417-1422
203. Yamashita S., and Melmed S. Insulin-like growth factor I action on rat anterior pituitary cells: suppression of growth hormone secretion and messenger ribonucleic acid levels. Endocrinology 118 (1986) 176-182
204. Young A. Inhibition of glucagon secretion. Adv Pharmacol 52 (2005) 151-171
205. Yung W., Leung P., Ng S., Zhang J., Chan S., and Chow B. Secretin facilitates GABA transmission in the cerebellum. J Neurosci 15 (2001) 7063-7068
206. Zaidi M., Moonga B., Bevis P., Bascal Z., and Breimer L. The calcitonin gene peptides: biology and clinical relevance. Crit Rev Clin Lab Sci 28 (1990) 109-174
207. Zhang K., Aruva M., Shanthly N., Cardi C., Patel C., Rattan S., et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific analogues for PET imaging of breast cancer: in vitro/in vivo evaluation. Regul Pept 144 (2007) 91-100